Introduction
============

Breast cancer is a heterogeneous disease, which is categorized into subtypes according to gene expressions and clinicopathological features ([@b1-ol-0-0-9853],[@b2-ol-0-0-9853]). Luminal subtype, which is one of the recognized subtypes, is characteristically estrogen receptor (ER) positive and human epidermal growth factor receptor type 2 (HER2) negative. Endocrine therapy is considered first, and then chemotherapy in high-risk groups, based on the pathological diagnosis which includes histological classification, tumor grade, the Ki67 labeling index (LI) and lymph node metastasis, as adjuvant systemic therapies ([@b3-ol-0-0-9853],[@b4-ol-0-0-9853]). However, some luminal tumors recur regardless of adjuvant therapy, which is a critical problem that must be overcome to improve patient survival ([@b5-ol-0-0-9853]).

The importance of tumor infiltrating lymphocytes (TILs) has increasingly been recognized in recent years ([@b6-ol-0-0-9853]--[@b9-ol-0-0-9853]). The host immune system appears to influence the development of breast carcinoma ([@b10-ol-0-0-9853]). In addition to these observations, chemotherapy might trigger recruitment of lymphocytes to tumor nests ([@b11-ol-0-0-9853],[@b12-ol-0-0-9853]). We also need to understand whether TILs have an important role in patients receiving endocrine therapy ([@b13-ol-0-0-9853],[@b14-ol-0-0-9853]). Therefore, we need to understand the biological features and functions of TILs in the breast cancer microenvironment. Many studies have compared TILs among breast cancers to determine their prognostic value. Abundant TILs in highly proliferative tumors such as triple negative breast cancer and HER2 positive breast cancer have been demonstrated ([@b15-ol-0-0-9853],[@b16-ol-0-0-9853]). In a recent study, marked TIL infiltration was found to be associated with better outcomes for patients with these subtypes ([@b17-ol-0-0-9853]--[@b23-ol-0-0-9853]). On the other hand, recruitment of TILs was also reported to have variable impacts on the outcomes of ER positive/HER2 negative breast cancers ([@b13-ol-0-0-9853],[@b15-ol-0-0-9853],[@b24-ol-0-0-9853]--[@b28-ol-0-0-9853]). However, details of TIL distributions are lacking as there have been few studies focusing on the timing of recurrence. In addition, the relationships between TIL distributions and the efficacies of systemic therapies such as chemotherapy and endocrine therapy remain poorly understood.

We retrospectively collected data from ER positive/HER2 negative breast cancer cases with early and late distant recurrence and from patients who remained recurrence free for more than ten years, and then identified clinicopathological factors predicting early and late recurrence in ER-positive/HER2 negative breast cancer cases ([@b29-ol-0-0-9853]--[@b31-ol-0-0-9853]). We next investigated the biological and prognostic significance of TILs, by comparing these three groups. We compared proportions of TILs among these groups and investigated associations between TIL distributions and clinicopathological factors in each group.

Materials and methods
=====================

### Cases and clinical samples

This retrospective multi-institution study was conducted as Scientific Research of the Japanese Breast Cancer Society ([@b29-ol-0-0-9853],[@b30-ol-0-0-9853]). We registered 223 consecutive patients with early distant recurrence and 149 consecutive patients with late distant recurrence of ER-positive/HER2 negative breast cancer, who had undergone breast surgery and/or neoadjuvant chemotherapy between January 2000 and December 2004, from nine institutions. These institutes were Okayama University, the Cancer Institute Hospital, the Japanese Foundation for Cancer Research, Hokkaido University, Juntendo University, National Health Organization (NHO) Osaka National Hospital, Kumamoto University, Kumamoto City Hospital, the NHO Hokkaido Cancer Center, and Nagoya City University. Early recurrence was diagnosed based on distant metastasis within 5 years, late recurrence as distant metastasis more than 5 years after initial treatment. For each late recurrence patient, in general, two age-matched patients free of recurrence for more than ten years were randomly selected using RAND in combination with Excel software at each institution. In total, 321 patients who had been recurrence free for more than ten years served as study controls. The study protocol was approved by the institutional review board (IRB) of each participating institution and conformed to the guidelines of the 1996 Declaration of Helsinki. Opting out and a waiver of informed consent were options, as anonymized archival specimens were used in this retrospective study.

Expressions of ER, PgR, HER2, and Ki67 LI were centrally assessed employing immunohistochemistry. HER2-positive tumors were excluded from this study. The details were documented in our previous report ([@b30-ol-0-0-9853]).

Hematoxylin and eosin (H&E) stained sections were available from 639 of the registered patients (early recurrence: n=184, late recurrence: n=134, no recurrence: n=321). In these cases with available sections, TIL proportions were compared among the three groups. We also assessed the relationships between TIL proportions and other clinicopathological features. Moreover, the relationship between TIL proportions and survival time after recurrence was evaluated for both groups with recurrent disease, i.e., both late and early recurrence.

### Evaluation of TILs

H&E-stained sections were utilized for evaluation of TILs. The percentages of stromal lymphocytes, serving as a predefined criterion in Denkert\'s *et al* and Loi\'s *et al* reports ([@b8-ol-0-0-9853],[@b25-ol-0-0-9853],[@b32-ol-0-0-9853]), were evaluated by two observers. Stromal TILs were measured as the percentage of immune cells in stromal tissue within the tumor that showed a mononuclear immunological infiltrate ([Fig. 1](#f1-ol-0-0-9853){ref-type="fig"}). Heterogeneous distributions were documented in almost all of the sections examined. Therefore, hot spots, cold spots, and Tertiary Lymphoid Structure were not taken into consideration in any of the measurements conducted; instead, one representative area was selected and evaluated. The findings were categorized according to three possible cut-off points for TIL proportions (10, 30, and 50%).

### Statistical analysis

Differences in clinicopathological data were compared between cases with and without recurrence employing the Chi-square test. The Chi square test was utilized when investigating associations between the TIL distribution and clinicopathological features in each group. The Kaplan-Meier method was used to estimate survival duration from the time-point of recurrence detection. Differences between overall survival curves were determined with the log-rank test. For both univariate and multivariate analyses, Cox regression was used to evaluate the influences of the variables on survival time. All of the data were analyzed employing JMP 11.0.0 (SAS Institute Inc., Cary, NC, USA) statistical software. A value of P\<0.05 was considered to indicate a statistically significant difference.

Results
=======

### Patient characteristics

Patient characteristics are presented in [Table I](#tI-ol-0-0-9853){ref-type="table"}. The median follow-up durations were 72 (range, 14--179), 133 (range, 67--177) and 128 (range, 57--179) months in the early, late and no recurrence groups, respectively. During follow-up of these 639 patients, 69.5% (128/184) of those with early recurrence and 31.3% (42/134) of those with late recurrence died of breast cancer. The histology was invasive ductal carcinoma in 94.0% (173/184), 93.2% (125/134) and 93.1% (299/321) of the early, late, and no recurrence groups, respectively. The recurrences were local in 20.1% (37/184) of the early recurrence group and in 28.3% (38/134) of the late recurrence group. Adjuvant endocrine therapy alone had been administered to 28.8% (53/184) of the early recurrence cases, 41.0% (55/134) of the late recurrence cases, and 56.0% (180/321) of the controls, while 53.8% (99/184), 51.4% (69/134) and 32.3% (104/321), respectively, received both adjuvant chemotherapy and endocrine therapy. The adjuvant chemotherapy consisted mainly of anthracyclines and/or taxanes.

### Distributions of TILs

The TIL distributions are shown in [Table II](#tII-ol-0-0-9853){ref-type="table"}. Percentages of TILs did not differ significantly among the three groups (P=0.556). In previous reports, various cut-off points were utilized (10, 35, 50 and 60%) ([@b14-ol-0-0-9853],[@b25-ol-0-0-9853],[@b27-ol-0-0-9853],[@b28-ol-0-0-9853],[@b33-ol-0-0-9853]). However, there are as yet no standardized cut-off points. We selected a 30% cut-off point from among the potential values because there were few cases with TIL proportions lower than 10% or more than 50% in our study. We thus conducted the following analyses employing 30% as the cut-off point.

In each case, various adjuvant therapies had been administered. Therefore, we investigated the TIL distributions according to the presence of adjuvant chemotherapy and endocrine therapy. The odds ratios for recurrence with high TILs are presented in [Table III](#tIII-ol-0-0-9853){ref-type="table"}. There were no significant interactions between TIL proportions and the time of recurrence in any of the subgroups. In those who had received adjuvant chemotherapy as well as endocrine therapy, a trend toward higher TIL proportions was detected when the early recurrence group was compared with the no recurrence group employing the 30% cut-off point (P=0.064).

### Associations of TIL proportions with clinicopathological factors

We assessed whether the proportion of TILs was associated with clinicopathological factors ([Table IV](#tIV-ol-0-0-9853){ref-type="table"}). TILs in breast cancer specimens correlated significantly with the Ki67 LI (P=0.002) in the early recurrence group. Nodal metastasis (P=0.008), tumor grade (P=0.008), and Ki67 LI (P=0.023) showed significant associations with the proportion of TILs in the late recurrence group. Nodal metastasis (P=0.004), ER status (P=0.045), PgR status (P=0.002), tumor grade (P=0.021), and Ki67 LI (P=0.002) showed significant associations with the proportion of TILs in the no recurrence group.

### Survival time after distant recurrence

We analyzed 318 cases (early recurrence: 184 (58%), late recurrence: 134 (42%)) to compare survival duration from the time of recurrence detection between the cases with high and low TIL proportions ([Fig. 2](#f2-ol-0-0-9853){ref-type="fig"}). The median follow-up duration from the detection of recurrence until death due to breast cancer was 39 (0--141) months in the early recurrence and 34 (0--89) months in the late recurrence group. The Kaplan-Meier method revealed a significant difference between these two groups in TIL distributions (P=0.026) ([Fig. 2](#f2-ol-0-0-9853){ref-type="fig"}). Moreover, the Kaplan-Meier method revealed a trend for higher TIL proportions in the early recurrence group (P=0.080), while there was no difference in the late recurrence group (P=0.187). Univariate analysis of all cases with recurrence revealed TILs, nodal metastasis, and tumor grade to be significant prognostic factors. We selected significant parameters (P\<0.20) from among various conventional confounding factors, and performed a multivariate analysis in which nodal metastasis, PgR, tumor grade, and Ki67 LI served as categorical variables. In this multivariate analysis, lymph node metastasis (P=0.027) was found to be an independent prognostic factor, while the proportion of TILs was not (P=0.200) ([Table V](#tV-ol-0-0-9853){ref-type="table"}).

Discussion
==========

In this retrospective study, the TIL proportions did not vary among recurrence patterns. However, among those receiving chemotherapy and endocrine therapy, cases with higher TIL proportions tended to have fewer recurrences, though the difference did not reach statistical significance. In ER positive breast cancer, the significance of TILs for predicting recurrence appears to be minor, but those cases showing TIL recruitment might benefit from chemotherapy. Higher proportions of TILs were also observed in cancers showing markedly proliferative phenotypes. Further study is needed to identify associations among lymphocyte recruitment, aggressive features of the tumor and responsiveness to chemotherapy.

Many researchers have focused on the significance of differences in TIL proportions among breast cancer cases ([@b7-ol-0-0-9853],[@b34-ol-0-0-9853]). Methods for TIL evaluation varied among these studies. The methods used ranged from evaluation of H&E sections for lymphocyte density and area, immune cell typing with immunohistochemistry and immune cell related transcriptome techniques ([@b35-ol-0-0-9853]--[@b43-ol-0-0-9853]). Many previous studies showed higher proportions of TILs to be observed in such de-differentiated tumors as triple negative breast cancer ([@b25-ol-0-0-9853],[@b33-ol-0-0-9853],[@b44-ol-0-0-9853]). As to pathological examinations, tumor grade and Ki67 LI both correlated with higher TIL proportions ([@b25-ol-0-0-9853]). However, in those with triple negative breast cancer, higher TIL proportions also indicated a better prognosis according to several reports ([@b44-ol-0-0-9853],[@b45-ol-0-0-9853]), while one study found that in ER positive breast cancer accompanied by less recruitment of TILs than the triple negative subtype, the TIL proportions lacked prognostic significance ([@b46-ol-0-0-9853]). On the other hand, according to a few studies, TILs also correlated with the outcomes of patients with ER positive breast tumors ([@b14-ol-0-0-9853],[@b33-ol-0-0-9853]). The conflicting results obtained in these studies may reflect different study populations and evaluation methods. We utilized H&E-stained sections to evaluate representative densities of lymphocytes in the stromal area. The data obtained in this case control study of luminal breast tumors were analyzed by comparing TIL proportions among recurrence patterns. We also evaluated time of recurrence in a long-term follow-up study.

In our full study population, TILs showed no correlation with the timing of recurrence. However, among those receiving chemotherapy and endocrine therapy, cases with higher TIL proportions tended to experience fewer recurrences, though the difference did not reach statistical significance. We speculated that patients with breast tumors showing higher TIL proportions might benefit more from chemotherapy. ER positive breast cancer patients received endocrine therapy, which was an important aspect of clinical management. Different adjuvant therapy modalities might make interpreting the roles of TILs difficult. Denkert *et al* ([@b32-ol-0-0-9853]) defined lymphocyte predominant breast cancer (LPBC) as showing evenly and widely distributed tumor lymphocytes in tumor nests ([@b16-ol-0-0-9853]). LPBC was defined as a mean density of TILs of at least 50%. However, most luminal breast cancers showed heterogeneous and low-density infiltration of lymphocytes into the stromal area. Therefore, identifying LPBC might not allow adequate evaluation of luminal breast tumors ([@b16-ol-0-0-9853]). Reliable methods for evaluating these heterogeneous distributions and the low density of TILs are as yet lacking. According to Vassiliki\'s report, investigation employing a 35% cut-off point as a binary parameter revealed an interaction between high TIL proportions and better outcomes, but this interaction was not statistically significant ([@b33-ol-0-0-9853]). According to Denkert\'s *et al* report, a high proportion of TILs is associated with a high pathological complete response rate ([@b27-ol-0-0-9853]). Jang and Kwon, employing a 10% cut-off value, reported high TIL proportions to be associated with better outcomes for luminal B (ER positive, HER2 negative, and higher Ki67) breast cancer patients who received adjuvant anthracycline ([@b28-ol-0-0-9853]). Higher TIL recruitment might make cancer cells more responsive to chemotherapy. The various cut-off points need to be investigated in terms of their significance when applied with various chemotherapy regimens. Studies utilizing ecological measurements and immune cell typing with immunohistochemistry have shown associations of lymphocytes, specifically their functions, with patient outcomes ([@b15-ol-0-0-9853],[@b35-ol-0-0-9853],[@b47-ol-0-0-9853]--[@b49-ol-0-0-9853]). The value of H&E-stained sections for determining lymphocyte density and area might be limited because the function of lymphocyte recruitment around tumor nests is not revealed by this method. Lymphocytes might promote or negatively regulate the growth of tumor nests. Flow cytometry, immunohistochemistry, and transcriptome analysis may be useful for determining the cell counts of specific lymphocyte populations. Further detailed studies, focusing on the function, extent and localization of tumor lymphocytes, are needed.

According to previous reports, high TIL proportions were found in aggressive breast cancer subtypes ([@b15-ol-0-0-9853],[@b25-ol-0-0-9853]). In our present study, in each group, TILs were identified in specimens from cases with a high Ki67 LI. Moreover, the TIL distribution correlated significantly with nodal metastasis, ER status, PgR status, tumor grade, and Ki67 LI in the no recurrence group. High TIL proportions correlated with rapid tumor growth, leading to death from breast cancer recurrence. Studies have demonstrated associations between high TIL proportions and poorer outcomes ([@b13-ol-0-0-9853],[@b26-ol-0-0-9853],[@b27-ol-0-0-9853]). On the other hand, several reports have noted an association between TIL proportions and the effects of chemotherapy ([@b15-ol-0-0-9853]). We speculated that infiltration and accumulation of TILs might reflect both the aggressiveness and the fragility of cancer cells, suggesting that patients would benefit from cytotoxic agents. However, minor clusters of TILs in luminal breast tumors appear to have little, if any, role in recurrence and thus might not be important when considering various adjuvant settings. On the other hand, patients with breast tumors showing TIL recruitment might have a slightly poorer prognosis after recurrence due to the aggressive nature of these tumors. Luminal subtype tumors are characteristically ER positive and HER2 negative, reflecting heterogeneous breast cancer biology. Hormonal treatment is considered first, and then chemotherapy in high-risk groups, based on the pathological diagnosis which includes histological classification, tumor grade, Ki67 LI and lymph node metastasis. Therefore, we need to investigate the significance of TILs as a predictive factor for selecting therapies such as chemotherapy, endocrine therapy and molecular targeted therapy among prospective cohorts in a well-planned adjuvant setting. TILs may serve as a surrogate marker for systemic therapies. Additional translational research is also required to fully investigate the significance of potential TIL biomarkers.

Our study is limited by its retrospective, case control design. Therapy selections and intervals varied among physicians. Our results might thus have been affected by selection bias. Also, our sample was small. Therefore, our conclusions are inevitably somewhat controversial. Verification of our findings requires a prospective, well-planned study with a large cohort. In the present study, we utilized a predefined cut-off point to categorize the subgroups according to different TIL proportions. This cut-off point was selected from among potential cut-off value candidates based on our dataset. Therefore, this cut-off point might not be optimal. An optimal cut-off point needs to be established, in a future study, based on the details of TIL proportions as a continuous parameter.

In our present study, recruitment of TILs was more often observed in aggressive phenotypes, such as ER positive, HER2 negative breast cancer, but did not significantly predict recurrence. However, higher TIL proportions were observed in breast cancer patients with aggressive biological phenotypes which tended to be more responsive to chemotherapy. The significance of stromal TILs for identifying patients likely to benefit from additional therapies merits investigation in a large future study.
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![Hematoxylin and eosin staining of TILs in breast tumor cells. Among stromal areas within tumor nests, a small number of TILs ranging from 10 to 29% were identified in (A), but in (B) TIL proportions exceeded 50% (magnification, ×400). TILs, tumor infiltrating lymphocytes.](ol-17-02-2177-g00){#f1-ol-0-0-9853}

![Survival time from recurrence detection until mortality due to breast cancer. There were significant differences in the (A) recurrence group as a whole. However, there was no significant difference in the (B) early recurrence group or in the (C) late recurrence group. TILs, tumor infiltrating lymphocytes.](ol-17-02-2177-g01){#f2-ol-0-0-9853}

###### 

Clinicopathological factors according to the time of recurrence.

                              Number (%)   P-value                                                                                                                                 
  --------------------------- ------------ ------------ ------------ ------------------------------------------------------ ------------------------------------------------------ ----------------------------------------------------
  Age (years)                                                                                                                                                                      
    ≤50                       82 (44.5)    49 (36.5)    120 (37.3)   0.113                                                  0.869                                                  0.151
    \>50                      102 (55.4)   85 (63.4)    201 (62.6)                                                                                                                 
  Menopausal status                                                                                                                                                                
    Post-                     90 (48.9)    81 (60.4)    171 (53.2)   0.345                                                  0.159                                                  0.041^[a](#tfn1-ol-0-0-9853){ref-type="table-fn"}^
    Pre-                      94 (51.0)    53 (39.5)    150 (46.7)                                                                                                                 
  Bilateral breast cancer                                                                                                                                                          
    Absent                    169 (91.8)   121 (90.3)   319 (99.3)   \<0.001^[c](#tfn3-ol-0-0-9853){ref-type="table-fn"}^   \<0.001^[c](#tfn3-ol-0-0-9853){ref-type="table-fn"}^   0.631
    Present                   15 (8.1)     13 (9.7)     2 (0.6)                                                                                                                    
  cT (mm)                                                                                                                                                                          
    ≤20                       49 (26.6)    44 (32.8)    187 (58.2)   \<0.001^[c](#tfn3-ol-0-0-9853){ref-type="table-fn"}^   \<0.001^[c](#tfn3-ol-0-0-9853){ref-type="table-fn"}^   0.23
    \>20                      135 (73.3)   90 (67.1)    134 (41.7)                                                                                                                 
  cN                                                                                                                                                                               
    Negative                  93 (50.5)    79 (58.9)    267 (83.1)   \<0.001^[c](#tfn3-ol-0-0-9853){ref-type="table-fn"}^   \<0.001^[c](#tfn3-ol-0-0-9853){ref-type="table-fn"}^   0.136
    Positive                  91 (49.4)    55 (41.0)    54 (16.8)                                                                                                                  
  Histological type                                                                                                                                                                
    IDC-NST                   171 (92.9)   124 (92.5)   297 (92.5)   0.864                                                  0.995                                                  0.892
    Others                    13 (7.0)     10 (7.4)     24 (7.4)                                                                                                                   
  Estrogen receptor (%)                                                                                                                                                            
    \<10                      16 (8.7)     10 (7.4)     27 (8.4)     0.396                                                  0.367                                                  0.915
    10--50                    57 (30.9)    43 (32.0)    82 (25.5)                                                                                                                  
    ≥50                       111 (60.3)   81 (60.4)    212 (66.0)                                                                                                                 
  Progesterone receptor (%)                                                                                                                                                        
    ≤20%                      85 (46.2)    59 (44.0)    133 (41.4)   0.298                                                  0.609                                                  0.701
    \>20%                     99 (53.8)    75 (55.9)    188 (58.5)                                                                                                                 
  Tumor grade                                                                                                                                                                      
    1 or 2                    131 (71.2)   106 (79.1)   278 (86.6)   \<0.001^[c](#tfn3-ol-0-0-9853){ref-type="table-fn"}^   \<0.001^[c](#tfn3-ol-0-0-9853){ref-type="table-fn"}^   0.107
    3                         53 (28.8)    28 (20.9)    43 (13.4)                                                                                                                  
  Ki 67(%)                                                                                                                                                                         
    ≤20                       136 (73.9)   114 (85.0)   265 (82.5)   \<0.001^[c](#tfn3-ol-0-0-9853){ref-type="table-fn"}^   0.507                                                  0.014^[a](#tfn1-ol-0-0-9853){ref-type="table-fn"}^
    \>20                      48 (26.0)    20 (14.9)    56 (17.4)                                                                                                                  
  Local recurrence                                                                                                                                                                 
    Absent                    136 (78.6)   96 (71.6)    0                                                                                                                          
    Present                   37 (21.3)    38 (28.3)    0                                                                                                                          
  Surgical treatment                                                                                                                                                               
    Total mastectomy          117 (63.5)   78 (58.2)    106 (33.0)   0.076                                                  \<0.001^[c](#tfn3-ol-0-0-9853){ref-type="table-fn"}^   0.331
    Partial mastectomy        67 (36.4)    56 (41.7)    215 (66.9)                                                                                                                 
  Radiation therapy                                                                                                                                                                
    Absent                    100 (54.3)   92 (68.6)    149 (46.4)   \<0.001^[c](#tfn3-ol-0-0-9853){ref-type="table-fn"}^   \<0.001^[c](#tfn3-ol-0-0-9853){ref-type="table-fn"}^   0.009^[b](#tfn2-ol-0-0-9853){ref-type="table-fn"}^
    Present                   84 (45.6)    42 (31.3)    172 (53.5)                                                                                                                 
  Adjuvant treatment                                                                                                                                                               
    none                      13 (7.0)     4 (2.9)      30 (9.3)     \<0.001^[c](#tfn3-ol-0-0-9853){ref-type="table-fn"}^   \<0.001^[c](#tfn3-ol-0-0-9853){ref-type="table-fn"}^   0.021^[a](#tfn1-ol-0-0-9853){ref-type="table-fn"}^
    chemotherapy only         19 (10.3)    6 (4.4)      7 (2.1)                                                                                                                    
    endocrine therapy only    53 (28.8)    55 (41.0)    180 (56.0)                                                                                                                 
    combined therapy          99 (53.8)    69 (51.4)    104 (32.4)                                                                                                                 
  Neoadjuvant chemotherapy                                                                                                                                                         
    Absent                    168 (91.3)   131 (97.7)   305 (95.3)   0.076                                                  0.198                                                  0.011^[a](#tfn1-ol-0-0-9853){ref-type="table-fn"}^
    Present                   16 (8.7)     3 (2.2)      15 (4.6)                                                                                                                   
  Chemotherapy                                                                                                                                                                     
    A+T                       54 (29.3)    22 (16.4)    42 (13.0)                                                                                                                  
    A                         39 (21.2)    31 (23.1)    40 (12.4)                                                                                                                  
    T                         6 (3.2)      7 (5.2)      13 (4.0)                                                                                                                   
    CMF                       17 (9.2)     12 (8.9)     13 (4.0)                                                                                                                   
    Others                    2 (1.0)      3 (2.2)      3 (0.9)                                                                                                                    
    None                      66 (35.8)    59 (44.0)    210 (65.4)                                                                                                                 
  Endocrine therapy                                                                                                                                                                
    TAM                       61 (33.1)    34 (25.3)    68 (21.1)                                                                                                                  
    TAM+LHRH                  30 (16.3)    18 (13.4)    35 (10.9)                                                                                                                  
    TAM→AI                    16 (8.7)     36 (26.8)    72 (22.4)                                                                                                                  
    TAM+LHRH→AI               1 (0.5)      3 (2.2)      15 (4.6)                                                                                                                   
    AI                        39 (21.2)    27 (20.1)    87 (27.1)                                                                                                                  
    LHRH                      5 (2.7)      6 (4.4)      7 (2.1)                                                                                                                    
    None                      32 (17.3)    10 (7.4)     37 (11.5)                                                                                                                  

P\<0.05

P\<0.01

P\<0.001. EarR, early recurrence; LateR, late recurrence; NoR, no recurrence; IDC-NST, invasive ductal carcinoma of no special type; A+T, anthracycline and taxane; A, anthracycline; T, taxane; CMF, cyclophosphamide, methotrexate, and fluorouracil; TAM, tamoxifen; TAM+LHRH, tamoxifen and luteinizing hormone-releasing hormone; TAM→AI, tamoxifen followed by aromatase inhibitor; TAM+LHRH→AI, tamoxifen and luteinizing hormone-releasing hormone followed by aromatase inhibitor; AI, aromatase inhibitor; LHRH, luteinizing hormone-releasing hormone; Ki67 Labeling index, Ki67 LI.

###### 

Differences in the distributions of TIL proportions among recurrence pattern.

            Number (%)                             
  --------- ------------ ------------ ------------ -------
  0-10%     11 (5.9)     4 (2.9)      17 (5.3)     0.556
  10-30%    151 (82.0)   113 (84.3)   261 (81.3)   
  30-50%    19 (10.3)    15 (11.1)    31 (9.6)     
  50-100%   3 (1.6)      2 (1.4)      12 (3.7)     

EarR, early recurrence; LateR, late recurrence; NoR, no recurrence; TILs, tumor infiltrating lymphocytes.

###### 

Odds ratios between recurrence patterns.

          Number with high TILs/total number   EarR vs. NoR   LateR vs. NoR   EarR vs. LateR                                
  ------- ------------------------------------ -------------- --------------- ---------------------- ---------------------- ----------------------
  All     22/184                               17/134         43/321          0.877 (0.499--1.505)   0.939 (0.502--1.686)   0.934 (0.476--1.859)
                                                                              P=0.64                 P=0.838                P=0.844
  CT+ET   13/99                                12/69          24/104          0.503 (0.234--1.041)   0.701 (0.315--1.494)   0.718 (0.304--1.703)
                                                                              P=0.064                P=0.363                P=0.447
  ET      5/53                                 4/55           15/180          1.145 (0.358--3.129)   0.862 (0.237--2.502)   1.328 (0.332--5.641)
                                                                              P=0.803                P=0.862                P=0.684

EarR, early recurrence; LateR, late recurrence; NoR, no recurrence; OR, odds Ratio; CI, confidence interval; CT, chemotherapy; ET, endocrine therapy; CT+ET, chemotherapy + endocrine therapy; TILs, tumor infiltrating lymphocytes.

###### 

Proportions of high and low TIL numbers in EarR, LateR, and NoR cases, in association with clinicopathological factors.

                              Number of TILs (%)                                                                                                                                                                             
  --------------------------- -------------------- ------------ ---------------------------------------------------- ----------- ------------ ---------------------------------------------------- ------------ ------------ ----------------------------------------------------
  TILs                                                                                                                                                                                                                       
    ≤50                       12 (54.5)            70 (43.2)    0.317                                                3 (17.6)    46 (39.3)    0.068                                                16 (37.2)    104 (37.4)   0.979
    \>50                      10 (45.4)            92 (56.7)                                                         14 (82.3)   71 (60.6)                                                         27 (62.7)    174 (62.5)   
  Tumor size (mm)                                                                                                                                                                                                            
    ≤20                       6 (27.2)             43 (26.5)    0.942                                                4 (23.5)    40 (34.1)    0.369                                                24 (55.8)    163 (58.6)   0.727
    \>20                      16 (72.7)            119 (73.4)                                                        13 (76.4)   77 (65.8)                                                         19 (44.1)    115 (41.3)   
  Lymph node metastases                                                                                                                                                                                                      
    Negative                  11 (50.0)            82 (50.6)    0.956                                                5 (29.4)    74 (63.2)    0.008^[b](#tfn7-ol-0-0-9853){ref-type="table-fn"}^   29 (67.4)    238 (85.6)   0.004
    Positive                  11 (50.0)            80 (49.3)                                                         12 (70.5)   43 (36.7)                                                         14 (32.5)    40 (14.3)    
  Estrogen receptor (%)                                                                                                                                                                                                      
    \<10                      1 (4.5)              15 (9.2)     0.622                                                1 (5.8)     9 (7.6)      0.917                                                8 (18.60)    19 (6.8)     0.045^[a](#tfn6-ol-0-0-9853){ref-type="table-fn"}^
    10--50                    6 (27.2)             51 (31.4)                                                         5 (29.4)    38 (32.4)                                                         12 (27.91)   70 (25.1)    
    ≥50                       15 (68.1)            96 (59.2)                                                         11 (64.7)   70 (59.8)                                                         23 (53.49)   189 (67.9)   
  Progesterone receptor (%)                                                                                                                                                                                                  
    ≤20%                      9 (40.9)             76 (46.9)    0.594                                                9 (52.9)    50 (42.7)    0.430                                                27 (62.7)    106 (38.1)   0.002^[b](#tfn7-ol-0-0-9853){ref-type="table-fn"}^
    \>20%                     13 (59.0)            86 (53.0)                                                         8 (47.0)    67 (57.2)                                                         16 (37.2)    172 (61.8)   
  Histological grade                                                                                                                                                                                                         
    1 or 2                    13 (59.0)            118 (72.8)   0.194                                                9 (52.9)    97 (82.9)    0.008^[b](#tfn7-ol-0-0-9853){ref-type="table-fn"}^   32 (74.4)    246 (88.4)   0.020^[a](#tfn6-ol-0-0-9853){ref-type="table-fn"}^
    3                         9 (40.9)             44 (27.1)                                                         8 (47.0)    20 (17.0)                                                         11 (25.5)    32 (11.5)    
  Ki 67 (%)                                                                                                                                                                                                                  
    ≤20                       10 (45.4)            126 (77.7)   0.002^[b](#tfn7-ol-0-0-9853){ref-type="table-fn"}^   11 (64.7)   103 (88.0)   0.023^[a](#tfn6-ol-0-0-9853){ref-type="table-fn"}^   28 (65.1)    237 (85.2)   0.002^[b](#tfn7-ol-0-0-9853){ref-type="table-fn"}^
    \>20                      12 (54.5)            36 (22.2)                                                         6 (35.2)    14 (11.9)                                                         15 (34.8)    41 (14.7)    

P\<0.05

P\<0.01. EarR, early recurrence; LateR, late recurrence; NoR, no recurrence; Ki67, Ki67 Labeling index; TILs, tumor infiltrating lymphocytes.

###### 

Univariate and multivariate analyses for survival time from recurrence detection until mortality due to breast cancer.

                                            Hazard ratio                                                                                       
  ----------------------------------------- ---------------------- ---------------------------------------------------- ---------------------- ----------------------------------------------------
  TILs ≤30/\>30                             1.598 (1.028--2.386)   0.037^[a](#tfn8-ol-0-0-9853){ref-type="table-fn"}^   1.348 (0.847--2.072)   0.200
  Age (years) ≤50/\>50                      1.160 (0.856--1.581)   0.338                                                Not selected           
  Bilateral breast cancer: absent/present   0.813 (0.438--1.376)   0.438                                                Not selected           
  cT ≤20/\>20                               1.062 (0.764--1.503)   0.721                                                Not selected           
  cN negative/positive                      1.500 (1.109--2.032)   0.008^[b](#tfn9-ol-0-0-9853){ref-type="table-fn"}^   1.412 (1.039--1.921)   0.027^[a](#tfn8-ol-0-0-9853){ref-type="table-fn"}^
  PgR \<20/≥20                              0.789 (0.582--1.072)   0.130                                                0.782 (0.575--1.065)   0.119
  Ki67 \<20/≥20                             1.270 (0.888--1.781)   0.184                                                1.176 (0.806--1.681)   0.391
  Tumor grade 1 or 2/3                      1.519 (1.080--2.105)   0.016^[a](#tfn8-ol-0-0-9853){ref-type="table-fn"}^   1.385 (0.976--1.937)   0.066

P\<0.05

P\<0.01. TILs, tumor infiltrating lymphocytes; PgR, progesterone receptor; Ki67, Ki67 Labeling index.

[^1]: ^11^*Present address*: Department of Breast Surgery, Kumamoto Shinto General Hospital, Kumamoto 862-8655, Japan
